On January 20, 2026, KAIN Technology, a company listed on the Science and Technology Innovation Board,(688687.SH) disclosed that it has withdrawn its drug registration application for Peicheng Interferon α-2 Injection (with the addition of hepatitis B indication).

Peicheng Interferon α-2 Injection is a marketed drug indicated for the treatment of chronic hepatitis C (HCV) in adults. It obtained drug registration approval and a new drug certificate in 2018.

In September 2024, KAIYIN Technology submitted an application for a new indication for the drug. The application withdrawn this time pertains to this newly submitted indication.

According to the latest review recommendations from the National Medical Products Administration ( NMPA) , and after careful consideration, the company has decided to voluntarily withdraw its drug registration application. It will further supplement its clinical case studies in accordance with the relevant requirements of the NMPA and resubmit the registration application as appropriate.

Kaiyin Technology has made a full provision for asset impairment on the development expenditures related to the Peiji Interferon α-2 Injection (with the addition of hepatitis B indication) project, which will reduce the total profit for 2025 by approximately RMB 111 million.

In the first three quarters of 2025, KAIN Technology's operating revenue was 927 million yuan, and its total profit was 131 million yuan. This withdrawal of the drug registration application is expected to have a significant impact on KAIN Technology's full-year performance in 2025.

https://finance.eastmoney.com/a/202601213625339838.html